Literature DB >> 30672837

PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics.

Rachel Huddart1, Russ B Altman1,2,3,4, Teri E Klein1,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30672837      PMCID： PMC6476683          DOI： 10.1097/FPC.0000000000000369

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  97 in total

1.  Determination of tropisetron in human plasma by liquid chromatography-tandem mass spectrometry.

Authors:  Pan Deng; Dafang Zhong; Xiaoyan Chen
Journal:  J Pharm Biomed Anal       Date:  2009-01-08       Impact factor: 3.935

2.  A mechanistic approach for the scaling of clearance in children.

Authors:  Andrea N Edginton; Walter Schmitt; Barbara Voith; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.

Authors:  L X Cubeddu; I S Hoffmann; N T Fuenmayor; A L Finn
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

4.  A combination of nonionic surfactants and iontophoresis to enhance the transdermal drug delivery of ondansetron HCl and diltiazem HCl.

Authors:  Sérgio M C Silva; Longsheng Hu; João J S Sousa; Alberto A C C Pais; Bozena B Michniak-Kohn
Journal:  Eur J Pharm Biopharm       Date:  2011-11-25       Impact factor: 5.571

5.  Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels.

Authors:  Y A Kuryshev; A M Brown; L Wang; C R Benedict; D Rampe
Journal:  J Pharmacol Exp Ther       Date:  2000-11       Impact factor: 4.030

6.  Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function.

Authors:  Camilo Rojas; Ajit G Thomas; Jesse Alt; Marigo Stathis; Jie Zhang; Edward B Rubenstein; Silvia Sebastiani; Sergio Cantoreggi; Barbara S Slusher
Journal:  Eur J Pharmacol       Date:  2009-10-15       Impact factor: 4.432

7.  A factorial trial of six interventions for the prevention of postoperative nausea and vomiting.

Authors:  Christian C Apfel; Kari Korttila; Mona Abdalla; Heinz Kerger; Alparslan Turan; Ina Vedder; Carmen Zernak; Klaus Danner; Ritva Jokela; Stuart J Pocock; Stefan Trenkler; Markus Kredel; Andreas Biedler; Daniel I Sessler; Norbert Roewer
Journal:  N Engl J Med       Date:  2004-06-10       Impact factor: 91.245

8.  The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron.

Authors:  V Fischer; A E Vickers; F Heitz; S Mahadevan; J P Baldeck; P Minery; R Tynes
Journal:  Drug Metab Dispos       Date:  1994 Mar-Apr       Impact factor: 3.922

9.  Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost.

Authors:  Hüseyin Abali; Ismail Celik
Journal:  Cancer Invest       Date:  2007 Apr-May       Impact factor: 2.176

10.  Pharmacokinetics and bioavailability study of two ondansetron oral soluble film formulations in fasting healthy male Chinese volunteers.

Authors:  Yubing Zhu; Qian Zhang; Jianjun Zou; Meng Wan; Zheng Zhao; Junrong Zhu
Journal:  Drug Des Devel Ther       Date:  2015-08-12       Impact factor: 4.162
View more
  2 in total

1.  Genetic Susceptibility Toward Nausea and Vomiting in Surgical Patients.

Authors:  Yvonne Gloor; Christoph Czarnetzki; François Curtin; Béatrice Gil-Wey; Martin R Tramèr; Jules A Desmeules
Journal:  Front Genet       Date:  2022-01-31       Impact factor: 4.599

Review 2.  Perspectives from the Society for Pediatric Research: pharmacogenetics for pediatricians.

Authors:  Sonya C Tang Girdwood; Katelyn M Rossow; Sara L Van Driest; Laura B Ramsey
Journal:  Pediatr Res       Date:  2021-04-06       Impact factor: 3.756
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.